News
Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...
Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.
Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...
INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...
The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...
Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...
The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.
14h
Stocktwits on MSNRegeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions
Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended ...
In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...
Regeneron Pharmaceuticals, Inc. saw a notable boost in its financial performance this quarter. The Public Sector Pension ...
After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...
Regeneron Pharmaceuticals, Inc. just received a hefty $54.5 million boost from Tocqueville Asset Management L.P. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results